Phthalates spotlight
This article was originally published in The Rose Sheet
Executive Summary
Controversy over phthalates safety will return to the forefront Nov. 19, when health advocates stage a news conference in Washington, D.C. urging industry to stop use of the ingredient in cosmetics. Briefing will coincide with Cosmetic Ingredient Review Expert Panel meeting in which board plans to consider phthalate safety. CIR reopened its safety assessment of dibutyl, diethyl and dimethyl phthalates in June (1"The Rose Sheet" June 24, 2002, p. 7)...
You may also be interested in...
Phthalates Safety Assessment Reopened By CIR
The Cosmetic Ingredient Review Expert Panel unanimously agreed to formally reopen its safety assessment of dibutyl, dimethyl and diethyl phthalates at a meeting in Washington, D.C. June 18-19
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.